A 71-year-old woman with a history of blurred vision in her right eye for nearly two months came to our attention. A complete ophthalmological evaluation, including best-corrected visual acuity measurement, fundus examination, spectral-domain optical coherence tomography, fluorescein angiography, and indocyanine green angiography, was performed. Multimodal imaging showed the presence of a polypoidal choroidal vasculopathy (PCV) lesion surrounded by diffuse hard exudates in the macular area. Our patient received three monthly intravitreal injections of brolucizumab during the loading phase, followed by an intravitreal injection every eight weeks for a total of 48 weeks of follow-up. The therapy appeared to be effective for improving both visual and anatomical outcomes revealing an important regression of the PCV and an almost complete reabsorption of lipid exudates. Intravitreal brolucizumab could be considered an effective treatment in the management of lipid exudation in PCV patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10685085 | PMC |
| http://dx.doi.org/10.7759/cureus.47942 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Enhancing anti-vascular endothelial growth factor with photodynamic therapy for polypoidal choroidal vasculopathy: A meta-analysis.
Surv Ophthalmol
December 2024
Department of Ophthalmology, Taipei City Hospital, Renai Branch, Taipei, Taiwan; Department of Special Education, University of Taipei, Taipei, Taiwan; Department of Ophthalmology, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. Electronic address:
Anti-vascular endothelial growth factor (VEGF) agents administered as either monotherapy or combination with verteporfin photodynamic therapy (PDT) are the 2 dominant treatment for polypoidal choroidal vasculopathy (PCV); However, controversies remain due to small sample sizes and inconsistency in prognosis from randomized controlled trials (RCTs). In accordance with the PRISMA statement, we investigated the efficacy of PDT plus anti-VEGF combination with anti-VEGF monotherapy. This study was accepted by the International Prospective Register of Systematic Reviews (CRD42023471362).
View Article and Find Full Text PDFA case of treating polypoidal choroidal vasculopathy subretinal fluid by subthreshold micropulse laser.
Am J Ophthalmol Case Rep
December 2024
Iraqi Ministry of Health, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq.
Purpose: Assess the effectiveness of a subthreshold micropulse laser for treating a patient with polypoidal choroidal vasculopathy and subretinal fluid.
Observations: A 55-year-old female presented with left eye blurring vision and metamorphopsia, and her visual acuity was 20/60. Optical coherence tomography (OCT) and OCT angiography showed subretinal fluid and pigmented epithelium detachment with a small polyp under the retinal pigmented epithelium, which was diagnosed as polypoidal choroidal vasculopathy.
Retrospective analysis of the etiology and drugs for vitreous hemorrhage caused by non-diabetic retinopathy and non-traumatic factors.
Hum Exp Toxicol
November 2024
Department of Fundus Disease, Tangshan Ophthalmology Hospital, Tangshan City, China.
Objective: To retrospectively analyze the etiology of non-diabetic retinopathy (DR) and non-traumatic vitreous haemorrhage (VH), and the effects of different anti-vascular endothelial growth factor (VEGF) drugs.
Methods: A retrospective analysis was conducted on VH patients diagnosed as non-diabetic retinopathy or trauma. Among 101 patients treated with anti-VEGF drugs, there were 48 cases in the Conbercept group and 53 cases in the Ranibizumab group.
[Efficacy of brolucizumab in the treatment of retinal pathologies: a review of post-marketing studies].
Vestn Oftalmol
November 2024
S.M. Kirov Military Medical Academy, Saint Petersburg, Russia.
Brolucizumab, an angiogenesis inhibitor, is a single-chain fragment of a humanized antibody used to treat neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). Although registration studies are the primary source of information on the new drug, post-marketing studies allow for further exploration and expansion of previous knowledge about its effectiveness, safety, and dosing regimens. This study summarizes the experience with brolucizumab from real-world clinical practice studies.
View Article and Find Full Text PDFShort-term fluctuation of intraocular pressure and influencing factors following intravitreal injection in patients with retinal vascular diseases.
Int J Ophthalmol
November 2024
Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Institute of Ophthalmology, Beijing Key Laboratory of Institute of Ophthalmology and Visual Sciences, Beijing 100730, China.
Aim: To investigate the patterns of short-term intraocular pressure (IOP) fluctuations and identify the contributing factors following intravitreal injection in patients with retinal vascular diseases.
Methods: Totally 81 patients were enrolled in this case control study. Eyes were categorized into 7 groups, including age-related macular degeneration (AMD), polypoidal choroidal vasculopathy (PCV), idiopathic choroidal neovascularization (CNV), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), macular edema secondary to branch (BVOME) and central (CVOME) retinal vein occlusion.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!